Commissioner Zaharieva recently discussed the new European Life Science Strategy, emphasizing the significant role life sciences have played in overcoming the COVID-19 pandemic. The strategy aims to make Europe a hub for innovation in life sciences, building on the achievements of decoding the virus, enabling mass testing, and developing vaccines.
The life sciences sector is a major contributor to the EU economy, adding nearly €1.5 trillion in value and supporting 29 million jobs across various fields including medicine and sustainable production. Commissioner Zaharieva noted that “Europe is home to over 40 of the top 100 life science universities” and stressed that while Europe ranks second in high-value patents after the US, there is room for growth.
The strategy outlines several initiatives to boost innovation and competitiveness within Europe. These include a new clinical research investment plan targeting multi-country trials and enhancing infrastructure. “This investment will target multi-country clinical trials and boost our excellent infrastructure,” said Zaharieva.
Advanced therapies such as cell or gene therapies are highlighted as potential game-changers for treating diseases like cancer and genetic disorders. The strategy includes plans to create a European Network of Centres of Excellence for advanced therapies to connect researchers working on these solutions.
Beyond human health, the strategy also addresses interconnected health systems involving humans, animals, and the planet. It emphasizes providing healthy food through resilient and sustainable food systems.
A key component of the strategy is modernizing regulations with a new Biotech Act to attract investors while ensuring public safety remains a priority. Additionally, measures will be considered to unlock data and AI potential in alignment with ethical principles.
Improving career prospects in life sciences is another focus area. The strategy aims to enhance STEM education and implement a new research careers framework within the European Research Area. “Leadership and competitiveness depend on talent,” stated Zaharieva.
The time horizon for implementing this strategy extends to 2030, with success hinging on partnerships between Member States, industry, and researchers. “Together, let’s make Europe the home of the next generation of life science innovation,” concluded Zaharieva.
